Tafalgie Therapeutics announces !

We are proud to announce that Tafalgie Therapeutics is one of only a handful of European companies (47 of which 12 are French, out of several thousand applications) to have won the European Innovation Council’s new gas pedal program for its new generation of pain-relieving peptides as an alternative to opioids.

After a rigorous selection process lasting almost 12 months, this recognition, which rewards companies demonstrating excellence in the deployment of radical and disruptive innovations, will enable the Marseille-based biotech to accelerate the development of its portfolio of molecules for the treatment of acute and chronic pain.

The next step is to launch clinical trials and demonstrate efficacy in humans.

Visit our contact page